Pharmaceutical Salts: Comprehensive Insights From Fundamental Chemistry to FDA Approvals (2019-2023)
- PMID: 39821716
- DOI: 10.1208/s12249-024-03020-4
Pharmaceutical Salts: Comprehensive Insights From Fundamental Chemistry to FDA Approvals (2019-2023)
Abstract
Pharmaceutical salts are a cornerstone in drug development, offering a robust, economical, and industry-friendly option for improving the crucial physicochemical properties of drugs, particularly solubility and dissolution. This review article explores all critical aspects of salt formation, including its importance, the basic chemistry involved, the principles governing counterion selection, the range of counterions used, and the methods for preparing salts along with their advantages and limitations. Additionally, it explores analytical techniques for confirming salt formation and the different approaches various countries adopt in considering new salts as intellectual property. Furthermore, the review sheds light on US FDA-approved salts from 2019 to 2023, providing a unique perspective by analyzing trends in counterion selection observed in FDA-approved salts during this period. Despite the extensive literature on pharmaceutical salts, a comprehensive review addressing all these critical aspects in a single article with a focus on current trends and particularly on US FDA-approved salts from 2019 to 2023 is lacking. This review bridges this gap by thoroughly exploring all mentioned facets of pharmaceutical salts and providing an up-to-date overview.
Keywords: Characterization; Mechanisms for dissolution improvement; Method of preparation; Pharmaceutical salts; Selection of counterions; Stages for salt selection; US-FDA approved salts.
© 2025. The Author(s), under exclusive licence to American Association of Pharmaceutical Scientists.
Conflict of interest statement
Declarations. Ethical: No human subjects or animals were used during this research work. Conflict of Interests: The authors declare no conflict of interest.
Similar articles
-
Recent developments in pharmaceutical salts: FDA approvals from 2015 to 2019.Drug Discov Today. 2021 Feb;26(2):384-398. doi: 10.1016/j.drudis.2020.11.016. Epub 2020 Nov 19. Drug Discov Today. 2021. PMID: 33221522 Review.
-
Carboxylic Acid Counterions in FDA-Approved Pharmaceutical Salts.Pharm Res. 2021 Aug;38(8):1307-1326. doi: 10.1007/s11095-021-03080-2. Epub 2021 Jul 23. Pharm Res. 2021. PMID: 34302256 Review.
-
Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database.J Med Chem. 2007 Dec 27;50(26):6665-72. doi: 10.1021/jm701032y. Epub 2007 Dec 1. J Med Chem. 2007. PMID: 18052022
-
Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.Drug Dev Ind Pharm. 2012 Jan;38(1):93-103. doi: 10.3109/03639045.2011.592530. Drug Dev Ind Pharm. 2012. PMID: 22118222
-
Modulation of biopharmaceutical properties of acidic drugs using cationic counterions: A critical analysis of FDA-approved pharmaceutical salts.Int J Pharm. 2021 Sep 25;607:120993. doi: 10.1016/j.ijpharm.2021.120993. Epub 2021 Aug 12. Int J Pharm. 2021. PMID: 34390812 Review.
Cited by
-
Development and Characterization of a New Oral Antileishmanial Bis(pyridine-2-Carboxamidine) Drug Through Innovative Dissolution Testing in Biorelevant Media Combined with Pharmacokinetic Studies.Pharmaceutics. 2025 Jun 26;17(7):838. doi: 10.3390/pharmaceutics17070838. Pharmaceutics. 2025. PMID: 40733047 Free PMC article.
References
-
- Bolla G, Sarma B, Nangia AK. Crystal engineering of pharmaceutical cocrystals in the discovery and development of improved drugs. Chem Rev. 2022;122(13):11514–603. - PubMed
-
- Lipinski C. Poor aqueous solubility—an industry wide problem in drug discovery. Am Pharm Rev. 2002;5(3):82–5.
-
- Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods. 2000;44(1):235–49. - PubMed
-
- Pindelska E, Sokal A, Kolodziejski W. Pharmaceutical cocrystals, salts and polymorphs: Advanced characterization techniques. Adv Drug Deliv Rev. 2017;117:111–46. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous